MediGene AG | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
10,166.00
14,976.00
46,759.00
52,630.00
51,724.00
51,408
Total Accounts Receivable
2,464.00
4,576.00
5,757.00
1,175.00
1,699.00
787
Inventories
3,046.00
4,406.00
6,654.00
7,866.00
7,724.00
7,298
Other Current Assets
587.00
708.00
730.00
2,302.00
2,195.00
2,703
Total Current Assets
16,263.00
24,666.00
59,900.00
63,973.00
63,342.00
62,196
Net Property, Plant & Equipment
405.00
951.00
2,502.00
3,323.00
4,329.00
4,261
Total Investments and Advances
6,200.00
6,904.00
13,337.00
6,157.00
5,982.00
25,622
Long-Term Note Receivable
242.00
385.00
-
-
-
-
Intangible Assets
29,170.00
38,377.00
35,713.00
35,767.00
36,292.00
36,225
Other Assets
375.00
-
2,079.00
2,495.00
1,992.00
1,286
Total Assets
52,655.00
71,283.00
113,531.00
111,715.00
111,937.00
129,590
ST Debt & Current Portion LT Debt
-
-
196.00
210.00
679.00
Accounts Payable
1,419.00
1,785.00
1,354.00
973.00
725.00
Income Tax Payable
463.00
-
-
-
-
Other Current Liabilities
3,210.00
5,970.00
8,114.00
10,783.00
8,404.00
Total Current Liabilities
5,092.00
7,755.00
9,664.00
11,966.00
9,808.00
Long-Term Debt
10,356.00
10,597.00
11,153.00
9,756.00
7,572.00
Provision for Risks & Charges
304.00
413.00
359.00
408.00
405.00
Deferred Taxes
-
2,353.00
1,951.00
1,621.00
2,179.00
Other Liabilities
627.00
1,094.00
416.00
9,372.00
5,806.00
Total Liabilities
16,379.00
22,212.00
23,543.00
33,123.00
25,770.00
Common Equity (Total)
36,276.00
49,071.00
89,988.00
78,592.00
86,167.00
Total Shareholders' Equity
36,276.00
49,071.00
89,988.00
78,592.00
86,167.00
Total Equity
36,276.00
49,071.00
89,988.00
78,592.00
86,167.00
Liabilities & Shareholders' Equity
52,655.00
71,283.00
113,531.00
111,715.00
111,937.00

About MediGene

View Profile
Address
Lochhamer Straße 11
Martinsried Bayern (Bavaria) 82152
Germany
Employees -
Website http://www.medigene.de
Updated 07/08/2019
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments.